Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05651204 · ClinicalTrials.gov registry record
GABA Biomarkers in Dravet Syndrome
A clinical trial of Dravet Syndrome, sponsored by Cook Children's Health Care System.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT05651204: Recruiting study of Dravet Syndrome, sponsored by Cook Children's Health Care System.
NCT05651204 is a study of Dravet Syndrome that is actively recruiting participants, run by Cook Children's Health Care System. The registered enrollment target is 36 participants, below the 107-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05651204, a study of Dravet Syndrome, is actively recruiting participants, sponsored by Cook Children's Health Care System.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical responses, correlate them with the BOLD responses, and with the levels of GABA in their blood.
Primary Outcome
GABA levels evaluated by clinical blood draw.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST GABA Blood Level
Study Locations (1)
Texas
- Cook Children's Medical Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2027-09-08 |
What NCT05651204 shows while recruiting
NCT05651204 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 107-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 1 intervention - of which GABA Blood Level is the first listed.
NCT05651204 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05651204 about?
NCT05651204 is a clinical study titled "GABA Biomarkers in Dravet Syndrome". This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical responses, correlate them with the BOLD responses, and with the levels of GABA in their blood.
What is the current status of trial NCT05651204?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2022-09-08. Estimated completion is 2027-09-08.
What conditions does trial NCT05651204 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT05651204?
The interventions under investigation include: GABA Blood Level (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05651204?
This trial is sponsored by Cook Children's Health Care System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05651204 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05651204's enrollment target sits among peer trials
36 10th of 12 higher than 3 of 12 other Dravet Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dravet Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
-
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
ACTIVE NOT RECRUITING · Phase 4
-
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI